Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Catalent is a global contract development and manufacturing organisation (CDMO) headquartered in Somerset, New Jersey, and established in 2007. It supports pharmaceutical development and drug-product manufacturing across the industry, including cGMP psychedelic drug-product programmes disclosed by clinical-stage sponsors. Catalent was acquired by Novo Holdings in 2024.
Manufacturing Snapshot
Established CDMO / ManufacturerScope & Capabilities
Supply Use Cases
GxP / Compliance
Facilities & Access
Global network with specialized oral dose and clinical/commercial manufacturing sites used by psychedelic-program sponsors.
Manufacturing DetailsSupported Substances
Incannex disclosed Catalent engagement for cGMP psilocybin drug-product development and manufacturing for PsiGAD/PSX-001. MindMed disclosed Catalent licensing for MM-120 ODT formulation technology.
Manufacturing Sources
Incannex Engages Catalent for cGMP Psilocybin Drug Product
https://www.globenewswire.com/news-release/2023/03/03/2620152/0/en/Incannex-Engages-Catalent-for-Development-and-cGMP-Manufacture-of-Psilocybin-Drug-Product-for-Clinical-Trials-and-Potential-Commercial-Use.html
MindMed License Agreement with Catalent for MM-120 ODT
https://mindmed.co/news/press-release/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120/
Quick Facts
- Founded
- 2007
- HQ
- United States
- Website
- Visit